NEW YORK (GenomeWeb News) – AdvanDx, a provider of molecular diagnostics for pathogen identification, said today that it has closed a $12 million Series B-1 financing round.

The financing will go toward expansion of the Woburn, Mass.-based company's product offerings and its sales and marketing operations in the US and abroad, it said.

Merck Global Health Innovation Fund led the round and was joined by existing investors SLS Ventures and LD Pensions.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

NPR reports that Turkish high school students will no longer study evolution.

Researchers report they sequenced and identified plant species in an "al fresco" laboratory.

An Australian team searches for genetic alterations linked to depression in hopes of developing personalized treatments, the Sydney Morning Herald reports.

In PNAS this week: host contributors to typhoid fever risk, effects of obesity-related variants near TMEM18, and more.